This case study followed a 34-year-old man with PSC and ulcerative colitis who did not respond to multiple advanced therapies, and who had a liver transplant. Before his liver transplant, he tried mesalamine and Remicade without achieving remission. After his liver transplant, his UC flared and he tried Remicade, Entyvio, Humira, Xeljanz, and Stelara. However, […]
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium
In this retrospective study, the Paediatric PSC Consortium compared the health of patients with PSC and IBD who had taken oral vancomycin (OV) to PSC-IBD patients who had not taken OV. Out of 113 patients with PSC-IBD, 70 were treated with OV, and they had a better chance of their IBD going into remission compared […]
Complete Biochemical Remission With Oral Vancomycin in a Patient With Primary Sclerosing Cholangitis and High Serum Immunoglobulin G4 Levels
This case study follows a 20-year old young man with ulcerative colitis and elevated AST, ALT, Alkaline Phosphatase, and IgG4, as well as narrowed bile ducts and liver inflammation and fibrosis. While steroids lowered his liver enzymes in the him short-term, they increased when he tapered off, so he was prescribed oral vancomycin (OV) at […]
How Frequent Are Vancomycin-Resistant Enterococci in patients with Primary Sclerosing Cholangitis and Ulcerative Colitis Treated With Oral Vancomycin?
This study followed seven adult patients with both PSC and ulcerative colitis. All patients were treated for at least six months with oral vancomycin doses between 250 mg – 1,500 mg per day. All patients achieved clinical remission with their ulcerative colitis. Labs that decreased included: fecal calprotectin, C-reactive protein, the Mayo score, alkaline phosphatase, […]
Dr. Ken Cox Presentation with Cincinnati Children’s Hospital: Treatment of Pediatric PSC with Oral Vancomycin
In this presentation, Dr. Ken Cox—the doctor who discovered the use of oral vancomycin for PSC—shares an enlightening presentation on this matter. Topics included are: • Dr. Cox’s experience treating children with PSC with oral vancomycin • Possible mechanisms in which oral vancomycin treats PSC • Long-term treatment of oral vancomycin • Effect of oral […]
Randomised Clinical Trial: Vancomycin or Metronidazole in Patients with Primary Sclerosing Cholangitis: A Pilot Study
In this 12-week pilot study, 35 adult PSC patients were randomized into one of 4 groups: 1. 125 mg oral vancomycin 4x/day 2. 250 mg oral vancomycin 4x/day 3. 250 mg metronizadole 3x/day 4. 500 mg metronizadole 3x/day One goal of this study was to investigate the safety and efficacy of these drugs. Another goal […]